

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claims 1-6, 21-24, and 31 without prejudice to renewal.

Please enter new claims 32-37, as shown below.

1.-6. (Cancelled)

7. (Original) A transgenic non-human animal comprising a transgene stably integrated into the genome of said animal, wherein said transgene comprises a nucleotide sequence encoding carboxyl-terminal truncated apoE operably linked to a promoter such that carboxyl-terminal truncated apoE-encoding sequences are expressed, and carboxyl-terminal truncated apoE protein is synthesized, in a neuron in said animal, and wherein, as a result of said synthesis of said carboxyl-terminal truncated apoE protein, said transgenic animal develops symptoms of AD.

8. (Original) The transgenic non-human animal of claim 7, wherein the transgenic nucleotide sequence encoding carboxyl-terminal truncated apoE is overexpressed, resulting in elevated levels of carboxyl-terminal truncated apoE relative to an animal of the same species not harboring said transgene.

9. (Original) The transgenic non-human animal of claim 7, wherein the apoE is apoE4.

10. (Original) The transgenic non-human animal of claim 9, wherein said carboxyl-terminal truncated apoE4 is apoE4(Δ 272-299).

11. (Original) The transgenic non-human animal of claim 7, wherein the symptom of AD is the presence of neurofibrillary tangles in a neuronal cell.

12. (Original) A method of screening for biologically active agents that modulate a phenomenon associated with Alzheimer's disease (AD), comprising:

- (a) contacting a cell that produces a carboxyl-terminal truncated apoE with a test agent;
and
- (b) determining the effect of said agent on the level of carboxyl-terminal apoE in the cell.

13. (Original) The method of claim 12, wherein the cell is a cell in a non-human transgenic animal that comprises, as a transgene, a nucleic acid that comprises a nucleotide sequence encoding apoE, and wherein a reduction in the level of carboxyl-terminal truncated apoE results in a reduction in neurofibrillary tangles.

14. (Original) The method of claim 12, wherein the cell is an *in vitro* cell.

15. (Original) A method of screening for biologically active agents that reduce a proteolytic activity of an enzyme that catalyzes the proteolytic degradation of apoE in a neuronal cell, comprising:
contacting the enzyme with a test agent and a substrate that provides a detectable product when acted on by the enzyme; and
determining the effect, if any, of the test agent on formation of detectable product.

16. (Original) The method of claim 15, wherein the substrate is a peptide of the formula $(P_3)_n P_2 P_1 - X$, wherein $P_4 P_3 P_2 P_1$ is a peptide, wherein X is a moiety that is linked to the carboxyl terminus of the peptide, and that provides a detectable signal when cleaved from the peptide upon action by the enzyme, P_1 is a hydrophobic residue selected from the group consisting of leucine, phenylalanine and methionine; P_2 is proline; P_3 is alanine, and $n \geq 2$.

17. (Original) An isolated cell comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes a carboxyl-terminal truncated form of apoE.

18. (Original) The isolated cell of claim 17, wherein the apoE is apoE4.

19. (Original) The isolated cell of claim 17, wherein said carboxyl-terminal truncated form of apoE4 is apoE4(Δ 272-299).

20. (Original) The isolated cell of claim 17, wherein said cell is a neuronal cell.

21.-24. (Cancelled)

25. (Original) A pharmaceutical preparation comprising:

a) an inhibitor of a chymotrypsin-like protease inhibitor;

- b) an agent selected from the group consisting of an acetylcholinesterase inhibitor, a non-steroidal anti-inflammatory agent, a cyclooxygenase-2 inhibitor, and a monoamine oxidase inhibitor; and
- c) a pharmaceutically acceptable excipient.

26. (Original) A method of treating Alzheimer's disease, the method comprising:

- a) assaying for the presence of carboxyl-terminal truncated apoE in a neuronal cell; and
- b) administering an inhibitor of an enzyme that catalyzes the formation of carboxyl-terminal truncated apoE in a neuronal cell.

27. (Original) A kit comprising:

a composition comprising an inhibitor of an enzyme that catalyzes the formation of carboxyl-terminal truncated apoE in a neuronal cell; and a pharmaceutically acceptable excipient; and instructions for administering the composition to an individual in need of thereof.

28. (Original) A method of treating Alzheimer's disease, the method comprising:

administering an inhibitor of a chymotrypsin-like serine protease in an amount effective to inhibit an enzyme that catalyzes the formation of carboxyl-terminal truncated apoE in a neuronal cell, wherein the enzyme is inhibited and the level of neurofibrillary tangles in a neuronal cell in the individual is reduced.

29. (Original) A composition comprising:

- a) an agent that inhibits an enzyme that catalyzes the formation of carboxyl-terminal truncated apoE in a neuronal cell; and
- b) a pharmaceutically acceptable excipient.

30. (Original) The composition according to claim 29, wherein the agent is selected from the group consisting of Ala-Ala-Pro-Phe (SEQ ID NO:1), Ala-Ala-Pro-Met (SEQ ID NO:2), Ala-Ala-Pro-Leu (SEQ ID NO:3), and Ala-Ala-Ala-Ala-Pro-Phe (SEQ ID NO:4).

31. (Cancelled)

32. (New) The method of claim 14, wherein the cell comprises a nucleic acid that comprises a nucleotide sequence that encodes a carboxyl-terminal truncated form of apoE.

33. (New) The method of claim 32, wherein the apoE is apoE4.

34. (New) The method of claim 33, wherein carboxyl-terminal truncated form of apoE4 is apoE4(Δ 272-299).

35. (New) The method of claim 14, wherein the cell is a neuronal cell.

36. (New) The method of claim 16, wherein X is selected from a chromogenic tag, a fluorogenic tag, a chemiluminescent tag, and a radiolabelled tag.

37. (New) The method of claim 16, wherein the peptide comprises the amino acid sequence Ala-Ala-Pro-Phe (SEQ ID NO:1.).